PRAVACHOL also significantly decreased the risk for undergoing myocardial revasculariza-tion procedures (coronary artery bypass graft [CABG] surgery or percutaneous transluminal coronary angioplasty [PTCA]) by 37% (80 vs 51 patients, p= 0.009) and coronary angiography by 31% (128 vs 90, p= 0.007). Cardiovascular deaths were decreased by 32% (73 vs 50, p= 0.03) and there was no increase in death from non-cardiovascular causes. Secondary Prevention of Cardiovascular Events In the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) 2 study, the effect of PRAVACHOL (pravastatin sodium), 40 mg daily, was assessed in 9014 patients (7498 men; 1516 women; 3514 elderly patients [age 65 years]; 782 diabetic patients) who had experi-enced either an MI (5754 patients) or had been hospitalized for unstable angina pectoris (3260 patients) in the preceding 3-36 months. Patients in this multicenter, double-blind, placebo-controlled study participated for an average of 5.6 years (median of 5.9 years) and at randomization had total cholesterol between 114 and 563 mg/ dL (mean 219 mg/ dL), LDL-C between 46 and 274 mg/ dL (mean 150 mg/ dL), triglycerides between 35 and 2710 mg/ dL (mean 160 mg/ dL), and HDL-C between 1 and 103 mg/ dL (mean 37 mg/ dL). At baseline, 82% of patients were receiving aspirin and 76% were receiving antihypertensive medication. Treatment with PRAVACHOL significantly reduced the risk for total mortality by reducing coro-nary death (see Table 1). The risk reduction due to treatment with PRAVACHOL on CHD mor-tality was consistent regardless of age. PRAVACHOL significantly reduced the risk for total mortality (by reducing CHD death) and CHD events (CHD mortality or nonfatal MI) in patients who qualified with a history of either MI or hospitalization for unstable angina pectoris. Table 1: LIPID Ð Primary and Secondary Endpoints Number (%) of Subjects Pravastatin 40 mg Placebo Risk | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
